BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 32352493)

  • 1. Safety and Vision Outcomes of Subretinal Gene Therapy Targeting Cone Photoreceptors in Achromatopsia: A Nonrandomized Controlled Trial.
    Fischer MD; Michalakis S; Wilhelm B; Zobor D; Muehlfriedel R; Kohl S; Weisschuh N; Ochakovski GA; Klein R; Schoen C; Sothilingam V; Garcia-Garrido M; Kuehlewein L; Kahle N; Werner A; Dauletbekov D; Paquet-Durand F; Tsang S; Martus P; Peters T; Seeliger M; Bartz-Schmidt KU; Ueffing M; Zrenner E; Biel M; Wissinger B
    JAMA Ophthalmol; 2020 Jun; 138(6):643-651. PubMed ID: 32352493
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and Efficacy Evaluation of rAAV2tYF-PR1.7-hCNGA3 Vector Delivered by Subretinal Injection in CNGA3 Mutant Achromatopsia Sheep.
    Gootwine E; Ofri R; Banin E; Obolensky A; Averbukh E; Ezra-Elia R; Ross M; Honig H; Rosov A; Yamin E; Ye GJ; Knop DR; Robinson PM; Chulay JD; Shearman MS
    Hum Gene Ther Clin Dev; 2017 Jun; 28(2):96-107. PubMed ID: 28478700
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Six Years and Counting: Restoration of Photopic Retinal Function and Visual Behavior Following Gene Augmentation Therapy in a Sheep Model of
    Ofri R; Averbukh E; Ezra-Elia R; Ross M; Honig H; Obolensky A; Rosov A; Hauswirth WW; Gootwine E; Banin E
    Hum Gene Ther; 2018 Dec; 29(12):1376-1386. PubMed ID: 29926749
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gene Augmentation Therapy Restores Retinal Function and Visual Behavior in a Sheep Model of CNGA3 Achromatopsia.
    Banin E; Gootwine E; Obolensky A; Ezra-Elia R; Ejzenberg A; Zelinger L; Honig H; Rosov A; Yamin E; Sharon D; Averbukh E; Hauswirth WW; Ofri R
    Mol Ther; 2015 Sep; 23(9):1423-33. PubMed ID: 26087757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term retinal cone rescue using a capsid mutant AAV8 vector in a mouse model of CNGA3-achromatopsia.
    Dai X; He Y; Zhang H; Zhang Y; Liu Y; Wang M; Chen H; Pang JJ
    PLoS One; 2017; 12(11):e0188032. PubMed ID: 29131863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cortical Visual Mapping following Ocular Gene Augmentation Therapy for Achromatopsia.
    McKyton A; Averbukh E; Marks Ohana D; Levin N; Banin E
    J Neurosci; 2021 Sep; 41(35):7363-7371. PubMed ID: 34349002
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of Methodology and Study Protocol: Safety and Efficacy of a Single Subretinal Injection of rAAV.hCNGA3 in Patients with CNGA3-Linked Achromatopsia Investigated in an Exploratory Dose-Escalation Trial.
    Kahle NA; Peters T; Zobor D; Kuehlewein L; Kohl S; Zhour A; Werner A; Seitz IP; Sothilingam V; Michalakis S; Biel M; Ueffing M; Zrenner E; Bartz-Schmidt KU; Fischer MD; Wilhelm BJC
    Hum Gene Ther Clin Dev; 2018 Sep; 29(3):121-131. PubMed ID: 30187779
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AAV-mediated cone rescue in a naturally occurring mouse model of CNGA3-achromatopsia.
    Pang JJ; Deng WT; Dai X; Lei B; Everhart D; Umino Y; Li J; Zhang K; Mao S; Boye SL; Liu L; Chiodo VA; Liu X; Shi W; Tao Y; Chang B; Hauswirth WW
    PLoS One; 2012; 7(4):e35250. PubMed ID: 22509403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vitreal delivery of AAV vectored Cnga3 restores cone function in CNGA3-/-/Nrl-/- mice, an all-cone model of CNGA3 achromatopsia.
    Du W; Tao Y; Deng WT; Zhu P; Li J; Dai X; Zhang Y; Shi W; Liu X; Chiodo VA; Ding XQ; Zhao C; Michalakis S; Biel M; Zhang Z; Qu J; Hauswirth WW; Pang JJ
    Hum Mol Genet; 2015 Jul; 24(13):3699-707. PubMed ID: 25855802
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genetics and Disease Expression in the CNGA3 Form of Achromatopsia: Steps on the Path to Gene Therapy.
    Zelinger L; Cideciyan AV; Kohl S; Schwartz SB; Rosenmann A; Eli D; Sumaroka A; Roman AJ; Luo X; Brown C; Rosin B; Blumenfeld A; Wissinger B; Jacobson SG; Banin E; Sharon D
    Ophthalmology; 2015 May; 122(5):997-1007. PubMed ID: 25616768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Gene Augmentation Therapy for a Missense Substitution in the cGMP-Binding Domain of Ovine CNGA3 Gene Restores Vision in Day-Blind Sheep.
    Gootwine E; Abu-Siam M; Obolensky A; Rosov A; Honig H; Nitzan T; Shirak A; Ezra-Elia R; Yamin E; Banin E; Averbukh E; Hauswirth WW; Ofri R; Seroussi E
    Invest Ophthalmol Vis Sci; 2017 Mar; 58(3):1577-1584. PubMed ID: 28282490
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comprehensive analysis of the achromatopsia genes CNGA3 and CNGB3 in progressive cone dystrophy.
    Thiadens AA; Roosing S; Collin RW; van Moll-Ramirez N; van Lith-Verhoeven JJ; van Schooneveld MJ; den Hollander AI; van den Born LI; Hoyng CB; Cremers FP; Klaver CC
    Ophthalmology; 2010 Apr; 117(4):825-30.e1. PubMed ID: 20079539
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Retinal morphology of patients with achromatopsia during early childhood: implications for gene therapy.
    Yang P; Michaels KV; Courtney RJ; Wen Y; Greninger DA; Reznick L; Karr DJ; Wilson LB; Weleber RG; Pennesi ME
    JAMA Ophthalmol; 2014 Jul; 132(7):823-31. PubMed ID: 24676353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term and age-dependent restoration of visual function in a mouse model of CNGB3-associated achromatopsia following gene therapy.
    Carvalho LS; Xu J; Pearson RA; Smith AJ; Bainbridge JW; Morris LM; Fliesler SJ; Ding XQ; Ali RR
    Hum Mol Genet; 2011 Aug; 20(16):3161-75. PubMed ID: 21576125
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Clinical Phenotype of CNGA3-Related Achromatopsia: Pretreatment Characterization in Preparation of a Gene Replacement Therapy Trial.
    Zobor D; Werner A; Stanzial F; Benedicenti F; Rudolph G; Kellner U; Hamel C; Andréasson S; Zobor G; Strasser T; Wissinger B; Kohl S; Zrenner E;
    Invest Ophthalmol Vis Sci; 2017 Feb; 58(2):821-832. PubMed ID: 28159970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A demonstration of cone function plasticity after gene therapy in achromatopsia.
    Farahbakhsh M; Anderson EJ; Maimon-Mor RO; Rider A; Greenwood JA; Hirji N; Zaman S; Jones PR; Schwarzkopf DS; Rees G; Michaelides M; Dekker TM
    Brain; 2022 Nov; 145(11):3803-3815. PubMed ID: 35998912
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gene therapy restores missing cone-mediated vision in the CNGA3-/- mouse model of achromatopsia.
    Michalakis S; Mühlfriedel R; Tanimoto N; Krishnamoorthy V; Koch S; Fischer MD; Becirovic E; Bai L; Huber G; Beck SC; Fahl E; Büning H; Schmidt J; Zong X; Gollisch T; Biel M; Seeliger MW
    Adv Exp Med Biol; 2012; 723():183-9. PubMed ID: 22183332
    [No Abstract]   [Full Text] [Related]  

  • 18. Novel mutations in the gene for α-subunit of retinal cone cyclic nucleotide-gated channels in a Japanese patient with congenital achromatopsia.
    Kuniyoshi K; Muraki-Oda S; Ueyama H; Toyoda F; Sakuramoto H; Ogita H; Irifune M; Yamamoto S; Nakao A; Tsunoda K; Iwata T; Ohji M; Shimomura Y
    Jpn J Ophthalmol; 2016 May; 60(3):187-97. PubMed ID: 27040408
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel CNGA3 and CNGB3 mutations in two Pakistani families with achromatopsia.
    Azam M; Collin RW; Shah ST; Shah AA; Khan MI; Hussain A; Sadeque A; Strom TM; Thiadens AA; Roosing S; den Hollander AI; Cremers FP; Qamar R
    Mol Vis; 2010 Apr; 16():774-81. PubMed ID: 20454696
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Three-year results of phase I retinal gene therapy trial for CNGA3-mutated achromatopsia: results of a non randomised controlled trial.
    Reichel FF; Michalakis S; Wilhelm B; Zobor D; Muehlfriedel R; Kohl S; Weisschuh N; Sothilingam V; Kuehlewein L; Kahle N; Seitz I; Paquet-Durand F; Tsang SH; Martus P; Peters T; Seeliger M; Bartz-Schmidt KU; Ueffing M; Zrenner E; Biel M; Wissinger B; Fischer D
    Br J Ophthalmol; 2022 Nov; 106(11):1567-1572. PubMed ID: 34006508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.